History of Prior Cancer Common in Newly Diagnosed Patients

Share this content:
History of Prior Cancer Common in Newly Diagnosed Patients
History of Prior Cancer Common in Newly Diagnosed Patients

MONDAY, Nov. 27, 2017 (HealthDay News) -- A substantial number of patients diagnosed with incident cancer in the United States have a prior history of cancer, according to a brief report published online Nov. 22 in JAMA Oncology.

Caitlin C. Murphy, Ph.D., M.P.H., from the University of Texas Southwestern Medical Center in Dallas, examined the prevalence of prior cancer among 740,990 persons newly diagnosed with cancer (from January 2009 through December 2013) using sequence numbers from the Surveillance, Epidemiology, and End Results program of cancer registries (1975 to 2013).

The researchers found that of the 765,843 incident cancers diagnosed during the study period, 18.4 percent (141,021) were a second order or higher primary cancer. A prior cancer history was detected in just over one-fourth of older (≥65 years) adults and 11 percent of younger adults newly diagnosed with cancer. There was wide variance in the prevalence of prior cancer (ranging from 3.5 to 36.9 percent) based on incident cancer type and age. Most prior cancers were diagnosed in a different cancer site than the incident cancer.

"Understanding the nature and impact of prior cancer is critical to improving clinical trial accrual and generalizability, disease outcomes, and patient experience," the authors write.

Abstract/Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »